Liquid Biopsy

Liquid Biopsy Liquid biopsy is always with you in the battle with cancer.

A sensor built partly from crab shells just detected circulating tumor DNA down to 10 femtomolar.We talk a lot about wha...
01/09/2026

A sensor built partly from crab shells just detected circulating tumor DNA down to 10 femtomolar.

We talk a lot about what liquid biopsy detects. This is about what the detection actually runs on.

A 2025/2026 study built a 3D nanofiber mesh from graphene oxide and chitosan, the marine-derived component, sourced from crustacean shell waste, to detect a specific cDNA methylation variant directly from patient blood.
The design works as a three-step signal chain:
O Capture: chitosan-graphene nanofibers form the physical scaffold
• Recognition: gold nanoparticle probes identify the specific cDNA target

• Amplification: an antibody-carbon nanotube complex boosts the signal enough to measure

Result: a reliable detection range of 50-10,000 fmol/L, with a limit of detection of 10 fmol/L, in clinical blood samples, not just a spiked buffer solution, which is where most biosensor papers stop.

Does knowing the sensor material change how you think about assay reliability? Or is that too far downstream to matter clinically? Drop your take below

Every liquid biopsy result depends on something almost nobody talks about: what the sensor is actually built from.We tal...
31/08/2026

Every liquid biopsy result depends on something almost nobody talks about: what the sensor is actually built from.
We talk endlessly about what liquid biopsy detects, cDNA, CTCs, exosomes. We rarely talk about what the detection surface is built from.

One of the more interesting answers right now: the ocean.

🌊Chitosan: from crustacean shell waste, the capture scaffold in emerging cDNA nanosensors

🌊Alginate: from brown algaex tunable, biodegradable nanocarrier chemistry

🌊Fucoidan: also from brown algae, emerging in biosensor and isolation platforms

They’re biocompatible, biodegradable, and sourced from what’s otherwise seafood-processing waste.

What these materials actually do inside a sensor, the 2026 data behind them, and why “what it’s made of” might matter as much as “what it detects.”

Materials science people, is sensor substrate chemistry something you’d want to see more of on a liquid biopsy page?

🩸Liquid biopsy has transformed cancer diagnostics, but biomarker detection remains a major challenge.Circulating tumor D...
18/08/2026

🩸Liquid biopsy has transformed cancer diagnostics, but biomarker detection remains a major challenge.

Circulating tumor DNA (ctDNA), exosomes, circulating tumor cells (CTCs), microRNAs, and proteins exist in extremely low concentrations in peripheral blood.

Traditional analytical techniques, including PCR and next-generation sequencing (NGS), offer high sensitivity, but they also present several limitations:
• High operational costs
• Complex sample preparation
• Long turnaround times
• Dependence on centralized laboratories

This is where marine-derived nanomaterials are attracting significant scientific attention.

Materials extracted from marine organisms, including chitosan, alginate, fucoidan, and marine-derived silica, possess unique physicochemical properties:
V High surface-area-to-volume ratios
V Superior biocompatibility
V Functional groups that enable biomolecular immobilization
VIEnhanced electrochemical activity

When integrated into biosensors, these materials can amplify signals and improve the detection of ultra-low-abundance biomarkers.

The ultimate goal isn’t simply to create more sensitive sensors.

It’s to detect disease earlier, when therapeutic interventions have the greatest impact.

Clinical question:
Could marine-derived biosensors eventually reduce our dependence on expensive molecular testing?

PrecisionMedicine ClinicalResearch

Liquid biopsy’s first decade proved the concept. This next one is about proving it at scale, in the clinic, for every pa...
12/08/2026

Liquid biopsy’s first decade proved the concept. This next one is about proving it at scale, in the clinic, for every patient who needs it.
A few places the field is pushing hardest right now: fragmentomics (reading DNA by shape, not just sequence), pairing blood signals with spatial maps of the tumor itself, exosomes carrying cargo cDNA can’t touch, and, maybe the real bottleneck, regulatory and reimbursement systems catching up to what the science can already do.
This September, EAR’s Liquid Biopsies 2026 conference brings the field together in Lyon to work through exactly this.
Expect this page covering it live.
What’s the biggest unlock liquid biopsy needs next?
Better sensitivity for early-stage disease
Clearer regulatory/reimbursement pathways
Larger prospective outcome trials
Lower cost, broader access
Vote in the comments and follow for the research shaping
what comes next.

Huge thanks to 2,505 of you.I’m genuinely grateful for this community, for choosing primary sources over hot takes, and ...
11/08/2026

Huge thanks to 2,505 of you.

I’m genuinely grateful for this community, for choosing primary sources over hot takes, and for showing up in the comments to ask thoughtful, important questions.

If this page has been useful, tag a colleague who’d want it in their feed.

Thank you for being here.

Multi-cancer early detection (MCED) is the most ambitious application of liquid biopsy, and the most scientifically dema...
04/08/2026

Multi-cancer early detection (MCED) is the most ambitious application of liquid biopsy, and the most scientifically demanding.

The core challenge, highlighted again in recent 2026 literature: at early stages, tumor fraction in blood is extremely low, and the signal has to be distinguished from:

🧬Clonal hematopoiesis (CH), age-related mutations from blood cells, not tumor, which can mimic a cancer signal

🧬Normal biological noise across a healthy population

🧬The reality that a “positive” result still requires a
tissue-of-origin prediction to be clinically actionable, a positive signal alone doesn’t tell a clinician where to look

Recent reviews summarizing the MCED landscape point to converging biomarker classes, cDNA methylation, fragmentomics, CTCs, microRNAs, and exosomal cargo, being combined into multi-analyte models, because no single analyte alone has shown adequate sensitivity for early-stage, asymptomatic disease across cancer types.

This is why MCED validation requires enormous prospective cohorts followed over years, not just retrospective case-control studies. The science is real; the population-level evidence is still catching up.

Clonal hematopoiesis (CH) is one of the single biggest confounders in cDNA testing. Many labs now sequence a matched white blood cell (buffy coat) sample alongside plasma specifically to filter out CH-derived variants before calling a mutation “tumor-derived.”

What would you need to see in the data before recommending MCED testing to an asymptomatic patient?

Minimal Residual Disease (MRD): The Post-Surgery Blind SpotMolecular residual disease (MRD) testing looks for ctDNA afte...
31/07/2026

Minimal Residual Disease (MRD): The Post-Surgery Blind Spot

Molecular residual disease (MRD) testing looks for ctDNA after surgery or during surveillance, when imaging is still clean.

What’s new in 2026:

📌 At this year’s ASCO Annual Meeting, Myriad Genetics presented new data on its whole-genome, personalized Precise MRD assay, reporting consistent detection of ctDNA at very low levels across multiple tumor types, reinforcing that assay sensitivity, not just presence/absence, is what will separate MRD platforms clinically.

📌 Natera’s Signatera received regulatory approval in Japan for colorectal cancer this year, the first PMDA-approved MRD test in that market, a meaningful signal for global MRD adoption.

📌 Ovarian cancer MRD is an emerging frontier: initial data from the MONSTAR-SCREEN-3 study used a whole-genome-sequencing-based ctDNA assay to detect molecular residual disease in ovarian cancer, extending MRD beyond its historical stronghold in colorectal and lung cancer.

The honest caveat: not every MRD-positive signal should trigger treatment escalation yet. In several NSCLC trials, MRD status has tracked strongly with outcomes but hasn’t yet proven it should independently drive therapy decisions , the field is still building that evidence base trial by trial.

MRD assays fall into two design philosophies:
1- tumor-informed (built from a patient’s own tumor sequencing, higher sensitivity, more specific),
2- tumor-naive/fixed-panel (no tissue needed, faster turnaround, broader eligibility).

The tradeoff between sensitivity and accessibility is one of the central design tensions in the field right now.

Tumor-informed vs tumor-naive MRD, which do you think wins out for routine surveillance at scale?

A single tube of blood can now tell us where a tumor is hiding, how it’s evolving, and whether treatment is working, bef...
30/07/2026

A single tube of blood can now tell us where a tumor is hiding, how it’s evolving, and whether treatment is working, before a scan ever could.

Liquid biopsy is built on 4 signals a tumor can’t help but leak into the bloodstream - cDNA, CTCs, exosomes, and methylation/fragmentomic signatures. 🧬

It’s not replacing tissue biopsy. It’s giving oncologists a live feed running alongside the static photograph: non-invasive, repeatable, and fast enough to track how a cancer changes in real time.

Swipe through & for how each signal works, and the science behind why early detection is still so hard.

Which use case are you most curious about - early detection, monitoring, or resistance tracking? Drop it in the comments

Follow for the research shaping this field, explained in plain language.

Every new entrant that combines deeper sequencing with AI-driven interpretation raises the bar for the entire field. Sen...
23/07/2026

Every new entrant that combines deeper sequencing with AI-driven interpretation raises the bar for the entire field. Sensitivity in early-stage cancer detection has historically been the hardest problem to solve, most circulating DNA in blood comes from healthy cells, not tumors. Whether Caris Detect closes that gap in real-world validation remains to be seen, but the direction is clear: liquid biopsy platforms are converging genomics, transcriptomics, and AI into a single readout.

Competition like this is good news for patients. It pressure-tests every player in the space to prove real clinical utility, not just technical capability.

📚 Liquid Biopsy | June Round-Up 2026, DeciBio

🔗 https://lnkd.in/e7eSfE7m

The 11-Day DifferenceIn advanced lung cancer, waiting for results isn’t neutral, it’s a clinical variable.Plasma-based c...
21/07/2026

The 11-Day Difference

In advanced lung cancer, waiting for results isn’t neutral, it’s a clinical variable.

Plasma-based ctDNA testing delivers a median turnaround of roughly 8-9 days, compared to about 15-20 days for tissue-based testing. In the NILE study, comprehensive plasma genotyping in untreated metastatic NSCLC patients matched or outperformed physician-selected tissue testing for identifying guideline-recommended biomarkers, and did it faster, with high concordance when both were available.

This isn’t a hypothetical efficiency gain. Faster biomarker identification means faster time to the right targeted therapy, particularly for patients whose tissue samples are limited or delayed, which happens in a meaningful share of real-world cases.

Liquid biopsy isn’t just “less invasive.” In time-sensitive treatment decisions, it can be the difference between starting the right therapy now versus weeks from now.

📚 Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction, Frontiers in Cell and Developmental Biology (2026)

🔗 https://lnkd.in/ezp75aWB

Address

Cambridge

Website

Alerts

Be the first to know and let us send you an email when Liquid Biopsy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category